Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26170180 | 0.86 | ESR2 (0.54) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL22239384 | 0.83 | ALOX5 (0.56) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL14478722 | 0.81 | MAP4K4 (0.50) | SMN1; SMN2MAPTRAB9ANPC1MAP4K4 | |
| SCHEMBL22239416 | 0.80 | FYN (0.56) | SMN1; SMN2MAPTLMNARAB9AKMT2A | |
| SCHEMBL25763756 | 0.80 | ESR2 (0.49) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL10017409 | 0.79 | CYP1A2 (0.50) | SMN1; SMN2MAPTRAB9AKMT2ANPC1 | |
| SCHEMBL2616121 | 0.79 | SMN1; SMN2 (0.54) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL22239389 | 0.79 | ESR2 (0.47) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL23514453 | 0.79 | SMN1; SMN2 (0.47) | ESR2SMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL24011728 | 0.79 | ESR2 (0.47) | ESR2SMN1; SMN2MAPTLMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| WO-2021087144-A1 | THERAPEUTIC METHODS USING VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159462-A1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | DIMT1, DLAT, COASY | ESR2 4721/4885SMN1; SMN2 1359/4885MAPT 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.